RxDoctor Payments Data

Brian Krustchinsky, PA

Physician Assistant · Temple, TXNPI 1952392953

Payments from drug & device makers

$818in general payments, 2019–2025

Across 25 payments — averaging $32.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$274
  • E.r. Squibb & Sons, L.L.C.$129
  • Boehringer Ingelheim$118
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$88
  • Pfizer$67
  • AstraZeneca$67
  • plus $75 from 3 others

What the payments were for

  • Food & beverage$818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$818 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$51,736
Medicare patients
415
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban531$609,584
XareltoRivaroxaban138$136,098
MultaqDronedarone Hcl60$85,487
JardianceEmpagliflozin15$16,155
Flecainide Acetate175$11,156
Amiodarone Hcl238$10,512
Metoprolol Succinate449$9,521
Diltiazem 24hr Er (Cd)Diltiazem Hcl102$4,446
SotalolSotalol Hcl85$3,726
Ranolazine ErRanolazine12$2,016
Losartan Potassium71$1,673
Atorvastatin Calcium65$1,659
Metoprolol Tartrate114$1,611
Carvedilol106$1,424
Propafenone Hcl14$1,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$609,584531 claims
Boehringer IngelheimJardiance$118$16,15515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →